BioCentury
ARTICLE | Clinical News

Qinprezo vosaroxin: Additional Phase Ib/II data

November 23, 2015 8:00 AM UTC

Data from 56 evaluable patients ages >=60 with previously untreated AML or high-risk MDS in an open-label, U.S. Phase Ib/II trial showed that IV Qinprezo on days 1 and 4 of each cycle plus decitabine led to an ORR of 77%, including 30 complete responses (CRs), 8 CRs with incomplete platelet recovery (CRp) and 5 CRs with incomplete hematological recovery (CRi). Median OS was 8.3 months and the 4- and 8-week mortality rates were 0% and 14%, respectively. The trial was sponsored by the University of Texas MD Anderson Cancer Center. Next month, data will be presented at the American Society of Hematology meeting in Orlando. Sunesis previously reported that the combination led to an ORR of 67% (see BioCentury, April 28, 2014). ...